The CYP2D6 4 polymorphism affects breast cancer survival in tamoxifen users

Breast Cancer Research and Treatment

Volumn 118, Issue 1, 2009, Pages 125-130

  Bijl, Monique J ^a   Van Schaik, Ron H N ^a   Lammers, Laureen A ^a   Hofman, Albert ^a   Vulto, Arnold G ^a   Van Gelder, Teun ^a   Stricker, Bruno H Ch ^a   Visser, Loes E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; CYP2D6; Polymorphism; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 4A; ENDOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG; 4 HYDROXYNORTAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; PRODRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NULL ALLELE; PRIORITY JOURNAL; RISK ASSESSMENT; AGED; ALLELE; BIOTRANSFORMATION; BREAST TUMOR; COHORT ANALYSIS; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; NETHERLANDS; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL;

AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; BREAST NEOPLASMS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRODRUGS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 70349910091     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0272-2     Document Type: Article

References (25)

1. WJ Louwman AC Voogd JA van Dijck, et al. 2008 On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands Cancer Causes Control 19 1 97 106 10.1007/s10552-007-9075-8 10.1007/s10552-007-9075-8 1:STN:280:DC%2BD1c%2FjvFOlug%3D%3D 18038250
2. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 22 1609 1618 10.1056/NEJM199811263392207 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D 9828250 (Pubitemid 28536137)
3. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
4. VC Jordan MM Collins L Rowsby G Prestwich 1977 A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity J Endocrinol 75 2 305 316 10.1677/joe.0.0750305 1:CAS:528:DyaE1cXmvFCrtQ%3D%3D 591813
5. V Stearns MD Johnson JM Rae, et al. 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 23 1758 1764 1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237
6. Z Desta BA Ward NV Soukhova DA Flockhart 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 3 1062 1075 10.1124/jpet.104.065607 10.1124/jpet.104.065607 1:CAS:528:DC%2BD2cXnt1eqtb0%3D 15159443 (Pubitemid 39108928)
7. M Ingelman-Sundberg SC Sim A Gomez C Rodriguez-Antona 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 3 496 526 10.1016/j.pharmthera.2007.09.004 10.1016/j.pharmthera.2007.09.004 1:CAS:528:DC%2BD2sXhtlCrs7bE 18001838 (Pubitemid 350116943)
8. C Sachse J Brockmoller S Bauer I Roots 1997 Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 2 284 295 1:CAS:528:DyaK2sXhtVCju74%3D 9012401
9. LD Bradford 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 2 229 243 10.1517/14622416.3. 2.229 10.1517/14622416.3.2.229 1:CAS:528:DC%2BD38XitlWqu70%3D 11972444 (Pubitemid 34223859)
10. A Gaedigk RR Gotschall NS Forbes SD Simon GL Kearns JS Leeder 1999 Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data Pharmacogenetics 9 6 669 682 10.1097/00008571-199912000-00002 10.1097/00008571-199912000-00002 1:CAS:528:DC%2BD3cXktVGitg%3D%3D 10634130
11. Y Jin Z Desta V Stearns, et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 1 30 39 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378
12. S Borges Z Desta L Li, et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 1 61 74 10.1016/j.clpt.2006.03.013 10.1016/j.clpt.2006.03.013 1:CAS:528:DC%2BD28Xms1enu7k%3D 16815318 (Pubitemid 43946844)
13. MP Goetz JM Rae VJ Suman, et al. 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 36 9312 9318 10.1200/JCO.2005.03.3266 10.1200/JCO.2005.03.3266 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D 16361630 (Pubitemid 46260189)
14. MP Goetz SK Knox VJ Suman, et al. 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 1 113 121 10.1007/s10549-006-9428-0 10.1007/s10549-006-9428-0 1:CAS:528: DC%2BD2sXisVylsg%3D%3D 17115111 (Pubitemid 47555336)
15. W Schroth L Antoniadou P Fritz, et al. 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 33 5187 5193 10.1200/JCO.2007.12.2705 10.1200/JCO.2007.12.2705 1:CAS:528:DC%2BD2sXhsVKnsbzN 18024866 (Pubitemid 350232249)
16. SA Nowell J Ahn JM Rae, et al. 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 3 249 258 10.1007/s10549-004-7751-x 10.1007/s10549-004-7751-x 1:CAS:528: DC%2BD2MXltFGqsLs%3D 15952058 (Pubitemid 40903087)
17. P Wegman L Vainikka O Stal, et al. 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 3 R284 R290 10.1186/bcr993 10.1186/bcr993 1:CAS:528:DC%2BD2MXitF2qtr0%3D 15987423
18. P Wegman S Elingarami J Carstensen O Stal B Nordenskjold S Wingren 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 1 R7 10.1186/bcr1640 10.1186/bcr1640 17244352 (Pubitemid 350215154)
19. TL Lash TP Ahern D Cronin-Fenton, et al. 2008 Modification of tamoxifen response: what have we learned? J Clin Oncol 26 10 1764 1765 10.1200/JCO.2007.15.5432 10.1200/JCO.2007.15.5432 18375910
20. A Hofman DE Grobbee PT de Jong FA van den Ouweland 1991 Determinants of disease and disability in the elderly: the Rotterdam Elderly Study Eur J Epidemiol 7 4 403 422 10.1007/BF00145007 10.1007/BF00145007 1:STN:280: DyaK38%2FgvVGmtw%3D%3D 1833235
21. A Hofman MM Breteler CM van Duijn, et al. 2007 The Rotterdam study: objectives and design update Eur J Epidemiol 22 11 819 829 10.1007/s10654-007- 9199-x 10.1007/s10654-007-9199-x 17955331 (Pubitemid 350105372)
22. MJ Bijl LE Visser A Hofman, et al. 2008 Influence of the CYP2D6 4 polymorphism on dose, switching and discontinuation of antidepressants Br J Clin Pharmacol 65 4 558 564 10.1111/j.1365-2125.2007.03052.x 10.1111/j.1365-2125. 2007.03052.x 1:CAS:528:DC%2BD1cXlt1Cgsbw%3D 18070221
23. Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247-2258. doi: 10.1002/1097-0142(20011101)92:9<2247: :AID-CNCR1570>3.0.CO;2-Y
24. JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 1 45 53 10.1016/S1470- 2045(07)70385-6 10.1016/S1470-2045(07)70385-6 18083636
25. RS Punglia HJ Burstein EP Winer JC Weeks 2008 Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis J Natl Cancer Inst 100 9 642 648 10.1093/jnci/djn100 10.1093/jnci/djn100 1:CAS:528:DC%2BD1cXlslymtbc%3D 18445827